Anti‑HER2‑targeted therapies for the treatment of advanced HER2‑positive breast cancer with brain metastases (Review)
- Authors:
- Zhangyan Wang
- Huangming Hong
-
Affiliations: Department of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610041, P.R. China - Published online on: March 26, 2025 https://doi.org/10.3892/mco.2025.2840
- Article Number: 45
-
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 4.0].
This article is mentioned in:
Abstract
|
Johnson JD and Young B: Demographics of brain metastasis. Neurosurg Clin N Am. 7:337–344. 1996.PubMed/NCBI | |
|
Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Pasquier D, Darlix A, Louvel G, Fraisse J, Jacot W, Brain E, Petit A, Mouret-Reynier MA, Goncalves A, Dalenc F, et al: Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort. Eur J Cancer. 125:22–30. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Lin NU, Amiri-Kordestani L, Palmieri D, Liewehr DJ and Steeg PS: CNS metastases in breast cancer: Old challenge, new frontiers. Clin Cancer Res. 19:6404–6418. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Watase C, Shiino S, Shimoi T, Noguchi E, Kaneda T, Yamamoto Y, Yonemori K, Takayama S and Suto A: Breast cancer brain metastasis-overview of disease state, treatment options and future perspectives. Cancers (Basel). 13(1078)2021.PubMed/NCBI View Article : Google Scholar | |
|
Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG and Byhardt R: Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 37:745–751. 1997.PubMed/NCBI View Article : Google Scholar | |
|
Siegel RL, Miller KD, Wagle NS and Jemal A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Tsukada Y, Fouad A, Pickren JW and Lane WW: Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer. 52:2349–2354. 1983.PubMed/NCBI View Article : Google Scholar | |
|
Raghunath A, Desai K and Ahluwalia MS: Current treatment options for breast cancer brain metastases. Curr Treat Options Oncol. 20(19)2019.PubMed/NCBI View Article : Google Scholar | |
|
Soffietti R, Abacioglu U, Baumert B, Combs SE, Kinhult S, Kros JM, Marosi C, Metellus P, Radbruch A, Villa Freixa SS, et al: Diagnosis and treatment of brain metastases from solid tumors: Guidelines from the European association of neuro-oncology (EANO). Neuro Oncol. 19:162–174. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Brown PD, Asher AL, Ballman KV, Farace E, Cerhan JH, Anderson SK, Carrero XW, Barker FG, Deming RL, Burri S, et al: NCCTG N0574 (Alliance): A phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases. J Clin Oncol. 33 (18 Suppl)(LBA4)2015. | |
|
Sneed PK, Mendez J, Vemer-van den Hoek JG, Seymour ZA, Ma L, Molinaro AM, Fogh SE, Nakamura JL and McDermott MW: Adverse radiation effect after stereotactic radiosurgery for brain metastases: Incidence, time course, and risk factors. J Neurosurg. 123:373–386. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Znidaric T, Gugic J, Marinko T, Gojkovic Horvat A, Paulin Kosir MS, Golo D, Ivanetic Pantar M and Ratosa I: Breast cancer patients with brain metastases or leptomeningeal disease: 10-year results of a national cohort with validation of prognostic indexes. Breast J. 25:1117–1125. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Gao C, Wang F, Suki D, Strom E, Li J, Sawaya R, Hsu L, Raghavendra A, Tripathy D and Ibrahim NK: Effects of systemic therapy and local therapy on outcomes of 873 breast cancer patients with metastatic breast cancer to brain: MD Anderson cancer center experience. Int J Cancer. 148:961–970. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Ferraro E, Reiner AS, Bou Nassif R, Tosi U, Brown S, Zeller S, Dang CT, Seidman AD and Moss NS: Survival among patients with ERBB2-positive metastatic breast cancer and central nervous system disease. JAMA Netw Open. 8(e2457483)2025.PubMed/NCBI View Article : Google Scholar | |
|
Bartsch R, Cameron D, Ciruelos E, Criscitiello C, Curigliano G, Duhoux FP, Foukakis T, Gligorov J, Harbeck N, LeVasseur N, et al: Expert recommendations on treatment sequencing and challenging clinical scenarios in human epidermal growth factor receptor 2-positive (HER2-positive) metastatic breast cancer. Cancer Treat Rev. 132(102853)2025.PubMed/NCBI View Article : Google Scholar | |
|
Rostami R, Mittal S, Rostami P, Tavassoli F and Jabbari B: Brain metastasis in breast cancer: A comprehensive literature review. J Neurooncol. 127:407–414. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Voldborg BR, Damstrup L, Spang-Thomsen M and Poulsen HS: Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol. 8:1197–1206. 1997.PubMed/NCBI View Article : Google Scholar | |
|
Dalle S, Thieblemont C, Thomas L and Dumontet C: Monoclonal antibodies in clinical oncology. Anticancer Agents Med Chem. 8:523–532. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Galanti D, Inno A, La Vecchia M, Borsellino N, Incorvaia L, Russo A and Gori S: Current treatment options for HER2-positive breast cancer patients with brain metastases. Crit Rev Oncol Hematol. 161(103329)2021.PubMed/NCBI View Article : Google Scholar | |
|
Valabrega G, Montemurro F and Aglietta M: Trastuzumab: Mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol. 18:977–984. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Vu T and Claret FX: Trastuzumab: Updated mechanisms of action and resistance in breast cancer. Front Oncol. 2(62)2012.PubMed/NCBI View Article : Google Scholar | |
|
Pardridge WM: Drug delivery to the brain. J Cereb Blood Flow Metab. 17:713–731. 1997.PubMed/NCBI View Article : Google Scholar | |
|
Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, van Dongen GA, Schröder CP, Lub-de Hooge MN and de Vries EG: Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 87:586–592. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Dawood S, Broglio K, Esteva FJ, Ibrahim NK, Kau SW, Islam R, Aldape KD, Yu TK, Hortobagyi GN and Gonzalez-Angulo AM: Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol. 19:1242–1248. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Garcia-Alvarez A, Papakonstantinou A and Oliveira M: Brain metastases in HER2-positive breast cancer: Current and novel treatment strategies. Cancers (Basel). 13(2927)2021.PubMed/NCBI View Article : Google Scholar | |
|
Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, Bohn KA, Adkins CE, Roberts A, Thorsheim HR, Gaasch JA, et al: Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res. 16:5664–5678. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Brufsky AM, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, Tripathy D, Tudor IC, Wang LI, Brammer MG, Shing M, et al: Central nervous system metastases in patients with HER2-positive metastatic breast cancer: Incidence, treatment, and survival in patients from registHER. Clin Cancer Res. 17:4834–4843. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Meng Y, Reilly RM, Pezo RC, Trudeau M, Sahgal A, Singnurkar A, Perry J, Myrehaug S, Pople CB, Davidson B, et al: MR-guided focused ultrasound enhances delivery of trastuzumab to Her2-positive brain metastases. Sci Transl Med. 13(eabj4011)2021.PubMed/NCBI View Article : Google Scholar | |
|
Tosi G, Duskey JT and Kreuter J: Nanoparticles as carriers for drug delivery of macromolecules across the blood-brain barrier. Expert Opin Drug Deliv. 17:23–32. 2020.PubMed/NCBI View Article : Google Scholar | |
|
McKeage K and Perry CM: Trastuzumab: A review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs. 62:209–243. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Nahta R, Hung MC and Esteva FJ: The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 64:2343–2346. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E, et al: Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): End-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 21:519–530. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Swain SM, Baselga J, Miles D, Im YH, Quah C, Lee LF and Cortés J: Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: Results from the randomized phase III study CLEOPATRA. Ann Oncol. 25:1116–1121. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Bergen ES, Binter A, Starzer AM, Heller G, Kiesel B, Tendl-Schulz K, Bago-Horvath Z, Furtner J, Leitner J, Exner R, et al: Favourable outcome of patients with breast cancer brain metastases treated with dual HER2 blockade of trastuzumab and pertuzumab. Ther Adv Med Oncol. 13(17588359211009002)2021.PubMed/NCBI View Article : Google Scholar | |
|
Lin NU, Pegram M, Sahebjam S, Ibrahim N, Fung A, Cheng A, Nicholas A, Kirschbrown W and Kumthekar P: Pertuzumab plus high-dose trastuzumab in patients with progressive brain metastases and HER2-positive metastatic breast cancer: Primary analysis of a phase II study. J Clin Oncol. 39:2667–2675. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Lin NU, Kumthekar P, Sahebjam S, Ibrahim N, Fung A, Cheng A, Nicholas A, Sussell J and Pegram M: Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data. NPJ Breast Cancer. 9(94)2023.PubMed/NCBI View Article : Google Scholar | |
|
Nordstrom JL, Gorlatov S, Zhang W, Yang Y, Huang L, Burke S, Li H, Ciccarone V, Zhang T, Stavenhagen J, et al: Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties. Breast Cancer Res. 13(R123)2011.PubMed/NCBI View Article : Google Scholar | |
|
Rugo HS, Im SA, Cardoso F, Cortés J, Curigliano G, Musolino A, Pegram MD, Wright GS, Saura C, Escrivá-de-Romaní S, et al: Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: A phase 3 randomized clinical trial. JAMA Oncol. 7:573–584. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Angeli E and Bousquet G: Brain metastasis treatment: The place of tyrosine kinase inhibitors and how to facilitate their diffusion across the blood-brain barrier. Pharmaceutics. 13(1446)2021.PubMed/NCBI View Article : Google Scholar | |
|
Wang W, He H, Marín-Ramos NI, Zeng S, Swenson SD, Cho HY, Fu J, Beringer PM, Neman J, Chen L, et al: Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer. Neuro Oncol. 23:1656–1667. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Chien AJ and Rugo HS: Tyrosine kinase inhibitors for human epidermal growth factor receptor 2-positive metastatic breast cancer: Is personalizing therapy within reach? J Clin Oncol. 35:3089–3091. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Traxler P: Tyrosine kinases as targets in cancer therapy-successes and failures. Expert Opin Ther Targets. 7:215–234. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Bachelot T, Romieu G, Campone M, Diéras V, Cropet C, Dalenc F, Jimenez M, Le Rhun E, Pierga JY, Gonçalves A, et al: Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): A single-group phase 2 study. Lancet Oncol. 14:64–71. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Kim IA, Winter KA, Sperduto PW, De Los Santos JF, Peereboom DM, Ogunleye T, Boulter D, Fritz JM, Cho KH, Shin KH, et al: Concurrent lapatinib with brain radiation therapy in patients with HER2+ breast cancer with brain metastases: NRG oncology-KROG/RTOG 1119 phase 2 randomized trial. Int J Radiat Oncol Biol Phys. 118:1391–1401. 2024.PubMed/NCBI View Article : Google Scholar | |
|
Blair HA: Pyrotinib: First global approval. Drugs. 78:1751–1755. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Yan M, Ouyang Q, Sun T, Niu L, Yang J, Li L, Song Y, Hao C, Chen Z, Orlandi A, et al: Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): A multicentre, single-arm, two-cohort, phase 2 trial. Lancet Oncol. 23:353–361. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Yan M, Ouyang Q, Sun T, Niu L, Yang J, Li L, Song Y, Hao C and Chen Z: Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases: 3-year follow-up results from the phase 2 PERMEATE trial. J Clin Oncol. 41 (16 Suppl)(S1048)2023.PubMed/NCBI View Article : Google Scholar | |
|
Yang Z, Meng J, Mei X, Mo M, Xiao Q, Han X, Zhang L, Shi W, Chen X, Ma J, et al: Brain radiotherapy with pyrotinib and capecitabine in patients with ERBB2-positive advanced breast cancer and brain metastases: A nonrandomized phase 2 trial. JAMA Oncol. 10:335–341. 2024.PubMed/NCBI View Article : Google Scholar | |
|
Xuhong JC, Qi XW, Zhang Y and Jiang J: Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer. Am J Cancer Res. 9:2103–2119. 2019.PubMed/NCBI | |
|
Awada A, Colomer R, Inoue K, Bondarenko I, Badwe RA, Demetriou G, Lee SC, Mehta AO, Kim SB, Bachelot T, et al: Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: The NEfERT-T randomized clinical trial. JAMA Oncol. 2:1557–1564. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Hurvitz SA, Saura C, Oliveira M, Trudeau ME, Moy B, Delaloge S, Gradishar W, Kim SB, Haley B, Ryvo L, et al: Efficacy of neratinib plus capecitabine in the subgroup of patients with central nervous system involvement from the NALA trial. Oncologist. 26:e1327–e1338. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Freedman RA, Gelman RS, Anders CK, Melisko ME, Parsons HA, Cropp AM, Silvestri K, Cotter CM, Componeschi KP, Marte JM, et al: TBCRC 022: A phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J Clin Oncol. 37:1081–1089. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Moulder SL, Borges VF, Baetz T, Mcspadden T, Fernetich G, Murthy RK, Chavira R, Guthrie K, Barrett E and Chia SK: Phase I study of ONT-380, a HER2 inhibitor, in patients with HER2+-advanced solid tumors, with an expansion cohort in HER2+ metastatic breast cancer (MBC). Clin Cancer Res. 23:3529–3536. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Lin NU, Borges V, Anders C, Murthy RK, Paplomata E, Hamilton E, Hurvitz S, Loi S, Okines A, Abramson V, et al: Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol. 38:2610–2619. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Lin NU, Murthy RK, Abramson V, Anders C, Bachelot T, Bedard PL, Borges V, Cameron D, Carey LA, Chien AJ, et al: Tucatinib vs placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with brain metastases: Updated exploratory analysis of the HER2CLIMB randomized clinical trial. JAMA Oncol. 9:197–205. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Chau CH, Steeg PS and Figg WD: Antibody-drug conjugates for cancer. Lancet. 394:793–804. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Barok M, Joensuu H and Isola J: Trastuzumab emtansine: Mechanisms of action and drug resistance. Breast Cancer Res. 16(209)2014.PubMed/NCBI View Article : Google Scholar | |
|
Krop IE, Lin NU, Blackwell K, Guardino E, Huober J, Lu M, Miles D, Samant M, Welslau M and Diéras V: Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: A retrospective, exploratory analysis in EMILIA. Ann Oncol. 26:113–119. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Krop IE, Kim SB, González-Martín A, LoRusso PM, Ferrero JM, Smitt M, Yu R, Leung AC and Wildiers H: TH3RESA study collaborators. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): A randomised, open-label, phase 3 trial. Lancet Oncol. 15:689–699. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, et al: RECIST 1.1-update and clarification: From the RECIST committee. Eur J Cancer. 62:132–137. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Montemurro F, Delaloge S, Barrios CH, Wuerstlein R, Anton A, Brain E, Hatschek T, Kelly CM, Peña-Murillo C, Yilmaz M, et al: Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: Exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial☆. Ann Oncol. 31:1350–1358. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Ogitani Y, Hagihara K, Oitate M, Naito H and Agatsuma T: Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 107:1039–1046. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Keam SJ: Trastuzumab deruxtecan: First approval. Drugs. 80:501–508. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N, Soma M, Okamoto H, Oitate M, Arakawa S, et al: DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res. 22:5097–5108. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Hurvitz S, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, et al: Abstract GS3-01: Trastuzumab deruxtecan (T-DXd; DS-8201a) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): Subgroup analyses from the randomized phase 3 study DESTINY-Breast03. Cancer Res. 82 (Suppl 4):GS3–01. 2022. | |
|
Hurvitz SA, Hegg R, Chung WP, Im SA, Jacot W, Ganju V, Chiu JWY, Xu B, Hamilton E, Madhusudan S, et al: Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 401:105–117. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Bartsch R, Berghoff AS, Furtner J, Marhold M, Bergen ES, Roider-Schur S, Starzer AM, Forstner H, Rottenmanner B, Dieckmann K, et al: Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: A single-arm, phase 2 trial. Nat Med. 28:1840–1847. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Lin NU, Lee EQ, Aoyama H, Barani IJ, Barboriak DP, Baumert BG, Bendszus M, Brown PD, Camidge DR, Chang SM, et al: Response assessment criteria for brain metastases: Proposal from the RANO group. Lancet Oncol. 16:e270–e278. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Bartsch R, Berghoff AS, Furtner J, Marhold M, Bergen ES, Roider-Schur S, Mair MJ, Starzer AM, Forstner H, Rottenmanner B, et al: Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases. Neuro Oncol. 26:2305–2315. 2024.PubMed/NCBI View Article : Google Scholar | |
|
Niikura N, Yamanaka T, Nomura H, Shiraishi K, Kusama H, Yamamoto M, Matsuura K, Inoue K, Takahara S, Kita S, et al: Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM). NPJ Breast Cancer. 9(82)2023.PubMed/NCBI View Article : Google Scholar | |
|
Pérez-García JM, Vaz Batista M, Cortez P, Ruiz-Borrego M, Cejalvo JM, de la Haba-Rodriguez J, Garrigós L, Racca F, Servitja S, Blanch S, et al: Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial. Neuro Oncol. 25:157–166. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Lin NU, Ciruelos EM, Jerusalem G, Müller V, Niikura N, Viale G, Oscroft E, Anand S, Walker G and Harbeck N: CLRM-14. Open-label, multinational, multicenter, phase 3B/4 study of trastuzumab deruxtecan (T-DXD) in patients with or without baseline brain metastasis (BM) with previously treated advanced/metastatic human epidermal growth factor receptor 2-positive breast cancer (HER2+ BC): Destiny-BREAST12. Neuro-Oncol Adv. 3 (Suppl 4)(iv4)2021. | |
|
Humphreys RC, Kirtely J, Hewit A, Biroc S, Knudsen N, Skidmore L and Wahl A: Abstract 639: Site specific conjugation of ARX-788, an antibody drug conjugate (ADC) targeting HER2, generates a potent and stable targeted therapeutic for multiple cancers. Cancer Res. 75 (15 Suppl)(S639)2015. | |
|
Hu X, Zhang Q, Wang L, Zhang J, Ouyang Q, Wang X, Li W, Xie W, Tong Z, Wang S, et al: ACE-breast-02: A randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer. Signal Transduct Target Ther. 10(56)2025.PubMed/NCBI View Article : Google Scholar | |
|
Barok M, Le Joncour V, Martins A, Isola J, Salmikangas M, Laakkonen P and Joensuu H: ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer. Cancer Lett. 473:156–163. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Yu J, Fang T, Yun C, Liu X and Cai X: Antibody-drug conjugates targeting the human epidermal growth factor receptor family in cancers. Front Mol Biosci. 9(847835)2022.PubMed/NCBI View Article : Google Scholar | |
|
Yao X, Jiang J, Wang X, Huang C, Li D, Xie K, Xu Q, Li H, Li Z, Lou L and Fang J: A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity. Breast Cancer Res Treat. 153:123–133. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Wang J, Liu Y, Zhang Q, Feng J, Fang J, Chen X, Han Y, Li Q, Zhang P, Yuan P, et al: RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: A pooled analysis of two studies. J Clin Oncol. 39 (15 Suppl)(S1022)2021. | |
|
Wang J, Liu Y, Zhang Q, Li W, Feng J, Wang X, Fang J, Han Y and Xu B: Disitamab vedotin, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpression and HER2-low advanced breast cancer: A phase I/Ib study. Cancer Commun (Lond). 44:833–851. 2024.PubMed/NCBI View Article : Google Scholar | |
|
Meric-Bernstam F, Beeram M, Mayordomo JI, Hanna DL, Ajani JA, Murphy MAB, Murthy RK, Piha-Paul SA, Bauer TM, Bendell JC, et al: Single agent activity of ZW25, a HER2-targeted bispecific antibody, in heavily pretreated HER2-expressing cancers. J Clin Oncol. 36 (15 Suppl)(S2500)2018. | |
|
Bartsch R and Bergen E: ASCO 2018: Highlights in HER2-positive metastatic breast cancer. Memo. 11:280–283. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Meric-Bernstam F, Beeram M, Hamilton E, Oh DY, Hanna DL, Kang YK, Elimova E, Chaves J, Goodwin R, Lee J, et al: Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: A phase 1, dose-escalation and expansion study. Lancet Oncol. 23:1558–1570. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Wang X, Lee KS, Zeng X, Sun T, Im YH, Li H, Wang K, Li H, Zhou P, Bao Y and Jiang Z: Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): Updated results from a phase 1b/2 study. J Clin Oncol. 41 (16 Suppl)(S1044)2023. | |
|
Wei H, Cai H, Jin Y, Wang P, Zhang Q, Lin Y, Wang W, Cheng J, Zeng N, Xu T and Zhou A: Structural basis of a novel heterodimeric Fc for bispecific antibody production. Oncotarget. 8:51037–51049. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Zhang J, Ji D, Cai L, Yao H, Yan M, Wang X, Shen W, Du Y, Pang H, Lai X, et al: First-in-human HER2-targeted bispecific antibody KN026 for the treatment of patients with HER2-positive metastatic breast cancer: Results from a phase I study. Clin Cancer Res. 28:618–628. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Liu M, Wang SJ and Ji Y: The i3+3 design for phase I clinical trials. J Biopharm Stat. 30:294–304. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Goyette MA, Stevens LE, DePinho CR, Seehawer M, Nishida J, Li Z, Wilde CM, Li R, Qiu X, Pyke AL, et al: Cancer-stromal cell interactions in breast cancer brain metastases induce glycocalyx-mediated resistance to HER2-targeting therapies. Proc Natl Acad Sci USA. 121(e2322688121)2024.PubMed/NCBI View Article : Google Scholar | |
|
Drago JZ, Modi S and Chandarlapaty S: Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 18:327–344. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Freedman R, Ren S, Tayob N, Gelman R, Smith KL, Davis R, Pereslete A, Attaya V, Cotter C, Chen WY, et al: Abstract PD7-03: Translational breast cancer research consortium trial 022: Neratinib and trastuzumab-emtansine for HER2+ breast cancer brain metastases (BCBM). Cancer Res. 83 (5 Suppl):PD7–03. 2023. | |
|
Hurvitz S, Loi S, O'Shaughnessy J, Okines A, Tolaney S, Sohn JH, Saura C, Zhu X, Cameron D, Bachelot T, et al: Abstract GS01-10: HER2CLIMB-02: Randomized, double-blind phase 3 trial of tucatinib and trastuzumab emtansine for previously treated HER2-positive metastatic breast caner. Cancer Res. 84 (Suppl 9):GS01–10. 2024.https://doi.org/10.1158/1538-7445.SABCS23-GS01-10. | |
|
Carey LA, Krop I, Ramos J, Feng W and Hamilton E: 331TiP HER2CLIMB-04: Phase II trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases. Ann Oncol. 32 (Suppl 5):S510–S511. 2021. | |
|
O'Sullivan CC, Ballman KV, McCall L, Kommalapati A, Zemla T, Weiss A, Mitchell M, Blinder V, Tung NM, Irvin WJ, et al: Alliance A011801 (compassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. Future Oncol. 17:4665–4676. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Xu M, Du X, Liu M, Li S, Li X, Fu YX and Wang S: The tumor immunosuppressive microenvironment impairs the therapy of anti-HER2/neu antibody. Protein Cell. 3:441–449. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Stagg J, Loi S, Divisekera U, Ngiow SF, Duret H, Yagita H, Teng MW and Smyth MJ: Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci USA. 108:7142–7147. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Yao H, Ryu MH, Park J, Voskoboynik M, Kim JH, Liu K, Barve M, Acuna-Villaorduna A, Im SA, Roy AC, et al: 656MO The HER2-targeting ADC SHR-A1811 in HER2-expressing/mutated advanced non-breast solid tumors (STs): Results from the global phase I study. Ann Oncol. 34 (Suppl 2):S461–S462. 2023. | |
|
Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, Xu X, Li X, Xu F, Fang Y, et al: Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 23:739–747. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Mercer JAM, DeCarlo SJ, Roy Burman SS, Sreekanth V, Nelson AT, Hunkeler M, Chen PJ, Donovan KA, Kokkonda P, Tiwari PK, et al: Continuous evolution of compact protein degradation tags regulated by selective molecular glues. Science. 383(eadk4422)2024.PubMed/NCBI View Article : Google Scholar | |
|
Gadd MS, Testa A, Lucas X, Chan KH, Chen W, Lamont DJ, Zengerle M and Ciulli A: Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat Chem Biol. 13:514–521. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Hu M, Li Y, Li J, Zhou H, Liu C, Liu Z, Gong Y, Ying B and Xie Y: Discovery of potent and selective HER2 PROTAC degrader based Tucatinib with improved efficacy against HER2 positive cancers. Eur J Med Chem. 244(114775)2022.PubMed/NCBI View Article : Google Scholar | |
|
Feins S, Kong W, Williams EF, Milone MC and Fraietta JA: An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 94 (S1):S3–S9. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Zhang BL, Qin DY, Mo ZM, Li Y, Wei W, Wang YS, Wang W and Wei YQ: Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors. Sci China Life Sci. 59:340–348. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Chen T, Wang M, Chen Y and Liu Y: Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors. Cancer Cell Int. 24(133)2024.PubMed/NCBI View Article : Google Scholar | |
|
Szöőr Á, Tóth G, Zsebik B, Szabó V, Eshhar Z, Abken H and Vereb G: Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies. Cancer Lett. 484:1–8. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Priceman SJ, Tilakawardane D, Jeang B, Aguilar B, Murad JP, Park AK, Chang WC, Ostberg JR, Neman J, Jandial R, et al: Regional delivery of chimeric antigen receptor-engineered T cells effectively targets HER2+ breast cancer metastasis to the brain. Clin Cancer Res. 24:95–105. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, Ostberg JR, Blanchard MS, Kilpatrick J, Simpson J, et al: Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med. 375:2561–2569. 2016.PubMed/NCBI View Article : Google Scholar |
